Home/Pipeline/Measovir®-based Prophylactic Vaccine (with Unither)

Measovir®-based Prophylactic Vaccine (with Unither)

Undisclosed

Research/Pre-clinicalEarly-stage collaboration

Key Facts

Indication

Undisclosed

Phase

Research/Pre-clinical

Status

Early-stage collaboration

Company

Oncovita

About Oncovita

Oncovita is a spin-off from Institut Pasteur dedicated to developing life-saving cancer treatments using its proprietary Measovir® platform, a modified measles virus vector. The company has secured exclusive worldwide licensing rights from Institut Pasteur and is advancing its lead candidate, MVdeltaC, for pleural mesothelioma, which has received FDA Orphan Drug Designation. Led by a seasoned management team, Oncovita is building a pipeline of oncolytic virus candidates and has established strategic partnerships with entities like Infinitusbio.AI and Unither Pharmaceuticals to accelerate development.

View full company profile

Therapeutic Areas

Oncology

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Technosphere Platform (New Formulations)	MannKind	Discovery/Preclinical	Active R&D
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active
Therapeutic Programs	Agathos Biologics	Pre-clinical	Active